
Antiverse and GlobalBio Inc. extend collaboration
AI specialist Antiverse Ltd (Cardiff, UK) and antobody engeeniering expert GlobalBio, Inc. (New York, USA) will be extending their collaboration to...

SeaBeLife secures €1.2m in funding
SeaBeLife SAS has secured €1.2m in funding, aiming to develop unique drug candidates that block cell necrosis and target two regulated cell death...

Germany boosts protein transition with €38m
Germany is set to follow countries such as the Denmark, the UK and the Netherlands, which this year provided massive funding to become world...

Novo Nordisk invests €2.1bn in production expansion
While Novo Nordisk’s main competitor Eli Lilly in the emerging market of effective drugs that fight obesity announced an investment of €11bn...

SOTIO Biotech licenses ADCs from Lonza subsidiary Synaffix BV
Lonza's centre of excellence, Synaffix B.V. (Amsterdam, The Netherlands) has entered a licensing agreement with immuno-oncology specialist SOTIO...

AstronauTx closes £48m Series A financing
The finanicing round of AstronauTx Ltd was led by the Novartis Venture Fund, with participation of MPM Capital, Brandon Capital, EQT Life Sciences,...

CEPI commits up to US$80m to University of Oxford to develop vaccines
The US$80m strategic partnership of CEPI, which was established in 2016 in the wake of the Ebola virus outbreak in west Africa, the University of...